WRAL Tech Wire

AstraZeneca sticks with Targacept on Alzheimer's drug development

The drug giant will conduct and fund phase 2 clinical trials of AZD1446, a compound that emerged from the partnership between AstraZeneca and Winston-Salem-based Targacept.

Targacept pushes ahead on its own with trials of two potential drugs

A compound called TC-5619 is being tested for treatments of schizophrenia and attention deficit-hyperactivity disorder.

Drug failure sends Targacept stock down 60%

Targacept's compound called TC-5214, which targets major depressive disorder, "did not meet its primary endpoint" in the Phase 3 clinical trial, the Winston-Salem based biopharma company says. CEO says other trials will continue.

Targacept's drug pipeline

Drug failure sends Targacept stock down 60%

Targacept's compound called TC-5214, which targets major depressive disorder, "did not meet its primary endpoint" in the Phase 3 clinical trial, the Winston-Salem based biopharma company says. CEO says other trials will continue.

Targacept's HQ

Targacept to move forward with anti-depressant trials

Failure in a Phase 3 clinical trial of a possible treatment of major depressive disorder sinks Targacept shares, but CEO says other trials will proceed.

Tech earnings: Pozen, DexOne, Biocryst, Furiex, Targacept

It's been a busy earnings week, and five North Carolina firms all reported losses.

Targacept to renew tests of potential Alzheimer's drug

A previous study in Alzheimer's disease over three months was inconclusive. Neither AZD3480 or commercially available donepezil met the primary target of the trial. After consulting with experts, the company believes it can get different results in a longer clinical study.

Targacept CEO keeps faith in potential ADHD drug

Drug giant AstraZeneca chose not to license the compound so the Winston-Salem based biopharma firm is proceeding with development on its own.

Targacept raises $80M through stock offering

The company turned to the stock market to raise funds for drug development following the ending of a partnership with GSK.

Targacept to raise $75M in stock offering

The Winston-Salem biopharmaceutical firm is looking to raise cash after losing GlaxoSmithKline as a partner.

New partnerships help Targacept's profit climb 85 percent

Targacept saw profits rise 85 percent last quarter compared to a year ago.

Targacept to report first quarter financials this week

Winston-Salem biopharma firm plans to report first quarter financial results on Thursday after U.S. markets close.

Targacept, GSK terminate drug development agreement

GSK had paid Targacept $30 million but has changed the focus of its drug development programs.

AstraZeneca payments lift Targacept to profitability for 2010

Triad beat: Investment firm BlackRock increases stake in Targacept

The Winston-Salem based biopharmaceutical firm also launches additional three clinical trials.

Targacept's HQ